Avenir Complete Post-Market Clinical Follow-Up Study
← catalyst calendarNCT04731077 · readout in 3,208 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
275actual
Sites
9
Countries
Denmark, Japan, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-27 | actual | When the study began enrolling |
| Primary completion | 2035-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis, Hip
- Avascular Necrosis of Hip
- Avascular Necrosis of the Femoral Head
- Post-traumatic; Arthrosis
Intervention
- Device: Avenir Complete Femoral Stem
Primary outcome
what the primary-completion date above is the date OFSurvival of the study device; whether or not it is still implanted in the subject
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed